These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 28368512)
1. Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer. Ho Y; Dehm SM Endocrinology; 2017 Jun; 158(6):1533-1542. PubMed ID: 28368512 [TBL] [Abstract][Full Text] [Related]
2. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226 [TBL] [Abstract][Full Text] [Related]
3. Androgen receptor splice variants in the era of enzalutamide and abiraterone. Nakazawa M; Antonarakis ES; Luo J Horm Cancer; 2014 Oct; 5(5):265-73. PubMed ID: 25048254 [TBL] [Abstract][Full Text] [Related]
4. Role of androgen receptor splice variants, their clinical relevance and treatment options. Wach S; Taubert H; Cronauer M World J Urol; 2020 Mar; 38(3):647-656. PubMed ID: 30659302 [TBL] [Abstract][Full Text] [Related]
5. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Coutinho I; Day TK; Tilley WD; Selth LA Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360 [TBL] [Abstract][Full Text] [Related]
6. Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations. Lu C; Brown LC; Antonarakis ES; Armstrong AJ; Luo J Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):381-397. PubMed ID: 32139878 [TBL] [Abstract][Full Text] [Related]
7. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance. Crona DJ; Milowsky MI; Whang YE Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358 [TBL] [Abstract][Full Text] [Related]
8. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Shafi AA; Yen AE; Weigel NL Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952 [TBL] [Abstract][Full Text] [Related]
9. Diverse Li Y; Yang R; Henzler CM; Ho Y; Passow C; Auch B; Carreira S; Nava Rodrigues D; Bertan C; Hwang TH; Quigley DA; Dang HX; Morrissey C; Fraser M; Plymate SR; Maher CA; Feng FY; de Bono JS; Dehm SM Clin Cancer Res; 2020 Apr; 26(8):1965-1976. PubMed ID: 31932493 [TBL] [Abstract][Full Text] [Related]
10. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Li Y; Chan SC; Brand LJ; Hwang TH; Silverstein KA; Dehm SM Cancer Res; 2013 Jan; 73(2):483-9. PubMed ID: 23117885 [TBL] [Abstract][Full Text] [Related]
11. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Zhu Y; Dalrymple SL; Coleman I; Zheng SL; Xu J; Hooper JE; Antonarakis ES; De Marzo AM; Meeker AK; Nelson PS; Isaacs WB; Denmeade SR; Luo J; Brennen WN; Isaacs JT Oncogene; 2020 Nov; 39(45):6935-6949. PubMed ID: 32989253 [TBL] [Abstract][Full Text] [Related]
12. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814 [TBL] [Abstract][Full Text] [Related]
13. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Yuan X; Cai C; Chen S; Chen S; Yu Z; Balk SP Oncogene; 2014 May; 33(22):2815-25. PubMed ID: 23752196 [TBL] [Abstract][Full Text] [Related]
14. Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation. Tummala R; Nadiminty N; Lou W; Evans CP; Gao AC Prostate; 2016 Apr; 76(5):445-55. PubMed ID: 26714839 [TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Wadosky KM; Koochekpour S Oncotarget; 2016 Sep; 7(39):64447-64470. PubMed ID: 27487144 [TBL] [Abstract][Full Text] [Related]
16. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Yu Z; Chen S; Sowalsky AG; Voznesensky OS; Mostaghel EA; Nelson PS; Cai C; Balk SP Clin Cancer Res; 2014 Mar; 20(6):1590-600. PubMed ID: 24449822 [TBL] [Abstract][Full Text] [Related]
17. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. Sharp A; Coleman I; Yuan W; Sprenger C; Dolling D; Rodrigues DN; Russo JW; Figueiredo I; Bertan C; Seed G; Riisnaes R; Uo T; Neeb A; Welti J; Morrissey C; Carreira S; Luo J; Nelson PS; Balk SP; True LD; de Bono JS; Plymate SR J Clin Invest; 2019 Jan; 129(1):192-208. PubMed ID: 30334814 [TBL] [Abstract][Full Text] [Related]
18. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer. Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685 [TBL] [Abstract][Full Text] [Related]
19. A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer. Han D; Gao S; Valencia K; Owiredu J; Han W; de Waal E; Macoska JA; Cai C Oncotarget; 2017 Jan; 8(4):6796-6808. PubMed ID: 28036278 [TBL] [Abstract][Full Text] [Related]
20. Downregulation of Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]